Comparativein vitrotranscriptomic analyses of COVID-19 candidate therapy hydroxychloroquine suggest limited immunomodulatory evidence of SARS-CoV-2 host response genes

Abstract

Hydroxychloroquine (HCQ) has emerged as a potential and controversial antiviral candidate therapy for COVID-19. While many clinical trials are underway to test the efficacy of HCQ as a treatment for COVID-19, underlying mechanisms of HCQ in the setting of COVID-19 remain unclear. Hence, we examined differential gene expression signatures of HCQ exposure, in vitro SARS-CoV-2 infection, and host signatures of COVID-19 in blood, bronchoalveolar lavage, and postmortem lung to evaluate whether HCQ transcriptome signatures associate with restoration of SARS-CoV-2-related host transcriptional responses. Here, we show that 24 hours of in vitro treatment of peripheral blood mononuclear cells(PBMC) with HCQ significantly impacted transcription of 16 genes involved in immune regulation and lipid metabolism. Using transcriptome data from in vitro SARS-CoV-2 infected NHBE and A549 cells and PBMC derived from confirmed COVID-19 infected patients, we determined that only 0.24% of the COVID-19 PBMC differentially expressed gene set and 0.39% of the in vitro SARS-CoV-2 cells differentially expressed gene set overlapped with HCQ-related differentially expressed genes. Moreover, we observed that HCQ treatment significantly impacted transcription of 159 genes in human primary monocyte-derived macrophages involved in cholesterol biosynthetic process and chemokine activity. Notably, when we compared the macrophage HCQ-related gene lists with genes transcriptionally altered during SARS-CoV-2 infection and in bronchoalveolar lavage of COVID-19+ patients, the CXCL6 gene was impacted in all three transcriptional signatures revealing evidence in favor of chemokine modulation. HCQrelated transcriptional changes minimally overlapped with host genes altered in postmortem lung biopsies from COVID-19 participants. These results may provide insight into the immunomodulation mechanisms of HCQ treatment in the setting of COVID-19 and suggest HCQ is not a panacea to SARS-CoV-2 infection.was not certified by peer review)

Identifying COVID-19-Specific Transcriptomic Biomarkers with Machine Learning Methods

“…The top-ranked features (genes/transcripts) and rules were identified by applying these optimal machine learning models. According to recent publications [44][45][46][47][48][49][50][51], several identified top-ranked features and rule-involved features have been confirmed to be associated with the infection of a specific kind of pathogen, thus validating the efficacy and accuracy of the prediction in the current work. The detailed discussion can be found below.…”

An aberrant STAT pathway is central to COVID-19

“…SARS-CoV-2 can also directly infect endothelial cells [8,26] and engineered human blood vessels in kidney organoids in vitro [27]. Among immune cells, SARS-CoV-2 appears to infect mononuclear phagocytes, but not lymphocytes [28,29].…”

Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine

“…CQ/HCQ inhibits the activation of monocytes, macrophages [75], and T cells, and thereby reduces the release of pro-inflammatory cytokines (IL1B, IL6, TNF, IFNG, and others) [76]. However, a recent in vitro study performed in peripheral blood mononuclear cells has revealed that HCQ has minimal immunomodulatory activity [77]; but it must be noted that this study was performed under non-stimulatory conditions and might not mimic inflammatory conditions observed in SARS-CoV-2 infection or other autoimmune and inflammatory diseases.…”